TransMedics Group Signals Growth Amid Margin Squeeze

Transmedics Group ((TMDX)) has held its Q1 earnings call. Read on for the main highlights of the call.

TransMedics Group’s latest earnings call struck a confident tone on growth while candidly acknowledging short-term margin pressure. Management highlighted 21% year-over-year revenue growth and a sizeable $462 million cash cushion, underscoring robust demand for its Organ Care System and transplant logistics services even as investments and donor volatility weigh on profitability.

Strong Top-Line Growth

TransMedics reported first-quarter 2026 revenue of $174 million, up about 21% year over year and 8% sequentially, signaling sustained demand despite operational headwinds. Management emphasized that this growth reflects deeper penetration of its OCS platform and continued uptake of National OCS Program services across major transplant centers.

U.S. and International Expansion

U.S. transplant revenue reached roughly $167 million, growing about 20% year over year and 8% sequentially, keeping the domestic business firmly in the driver’s seat. International revenue, while still modest at around $5.6 million, surged 39% year over year and 17% sequentially, showing early but accelerating traction abroad.

Product and Service Momentum

Product revenue came in near $108 million, up about 22% from a year ago and 8% quarter over quarter, as hospitals increased adoption of OCS devices. Service revenue of roughly $66 million rose 19% year over year and 9% sequentially, with logistics and aviation utilization providing a meaningful boost to the services mix.

Profitability and Cash Strength

Adjusted operating income was about $18 million, implying a roughly 10% adjusted operating margin despite elevated spending, while adjusted net income reached $11 million or $0.30 per share. The company ended the quarter with about $462 million in cash and equivalents, giving ample firepower to fund clinical trials, fleet expansion and global rollout plans.

Multi-Front Growth Roadmap

Management reiterated its 2026 revenue outlook of $727 million to $757 million, or 20% to 25% growth, backed by several parallel initiatives rather than a single bet. Key pillars include ENHANCE and DENOVO trials, the CHOPS controlled hypothermic system, next-generation OCS Kidney 3.0 targeting an early-2027 IDE, Gen 3.0 upgrades for other organs and a push to scale NOP operations in Europe.

Operational Logistics Strength

The company maintained about 82% coverage of NOP missions requiring air transport, highlighting logistics as a strategic differentiator in organ procurement. TransMedics plans to keep 22 aircraft active in the U.S. this year and intends to double-shift parts of the fleet to drive utilization and create capacity for incremental case volume.

Gross Margin Pressure

Total gross margin came in around 58%, down roughly 331 basis points from a year earlier, as the company replenished inventory and ramped internal supply chain activity for ENHANCE and DENOVO. Additional investment in NOP capabilities and certain one-time factors also weighed on margins, though management reiterated a long-term gross margin target of around 60%.

Rising Operating Expenses

Adjusted operating expenses climbed to about $83 million, up 42% year over year and 17% sequentially, reflecting a deliberate acceleration in spending. Adjusted R&D jumped roughly 45% on OCS Kidney, Gen 3.0 and Mirandola initiatives, while adjusted SG&A rose about 41% as the company expanded the NOP network, relocated headquarters and stepped up international efforts.

Clinical Enrollment Delays

ENHANCE and DENOVO clinical enrollment has been slower than expected due to competitive responses and market confusion, with management not expecting near-term revenue contributions from these programs. To reduce dependence on third-party cold storage as a control arm, the company is pursuing CHOPS as an FDA-regulated alternative that could tighten trial design and execution.

Donor Volume Volatility

TransMedics noted that diseased donor volumes have been softer than anticipated amid changes tied to the U.S. Transplant Modernization Act and updates to the national allocation system. The company views this as a transient disruption but acknowledged that the timing of donor volume normalization remains uncertain, adding an element of near-term revenue variability.

Early-Stage International Dynamics

While international revenue is growing at a rapid percentage clip, management stressed that it remains a small slice of the business and is prone to quarterly swings. Factors such as reimbursement decisions, tender timing and local market dynamics in Europe could make results lumpy as TransMedics builds out its footprint and executes new partnerships.

Margin Guidance and Variability

Management guided that adjusted operating margin could run up to about 250 basis points below 2025 levels in the near term, given front-loaded investments across R&D, logistics and global expansion. The company declined to offer quarterly phasing detail and cautioned that margin trends may be uneven through the year as clinical enrollment and U.S. modernization effects evolve.

Forward-Looking Outlook

TransMedics reaffirmed its full-year 2026 revenue guide of $727 million to $757 million, implying 20% to 25% growth on top of an already larger base. While the company signaled confidence in its long-term gross margin target and strategic trajectory, it left the door open to revisiting guidance as ENHANCE and DENOVO progress and as the impact of U.S. transplant policy changes becomes clearer.

TransMedics’ earnings call painted the picture of a high-growth company intentionally trading some near-term margin for strategic positioning in a complex transplant ecosystem. Investors will now watch whether clinical enrollment accelerates, donor volumes stabilize and new platforms like CHOPS and OCS Kidney Gen 3.0 convert today’s investment cycle into durable, profitable growth.